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and Holger Krakowski-Roosen1Abstract
Background: Cancer cachexia is a progressive wasting syndrome and the most prevalent characteristic of cancer
in patients with advanced pancreatic adenocarcinoma. We hypothesize that genes expressed in wasted skeletal
muscle of pancreatic cancer patients may determine the initiation and severity of cachexia syndrome.
Experimental design: We studied gene expression in skeletal muscle biopsies from pancreatic cancer patients with
and without cachexia utilizing Real-Imaging cDNA-AFLP-based transcript profiling for genome-wide expression
analysis.
Results: Our approach yielded 183 cachexia-associated genes. Ontology analysis revealed characteristic changes
for a number of genes involved in muscle contraction, actin cytoskeleton rearrangement, protein degradation,
tissue hypoxia, immediate early response and acute-phase response.
Conclusions: We demonstrate that Real-Imaging cDNA-AFLP analysis is a robust method for high-throughput
gene expression studies of cancer cachexia syndrome in patients with pancreatic cancer. According to quantitative
RT-PCR validation, the expression levels of genes encoding the acute-phase proteins α-antitrypsin and fibrinogen α
and the immediate early response genes Egr-1 and IER-5 were significantly elevated in the skeletal muscle of
wasted patients. By immunohistochemical and Western immunoblotting analysis it was shown, that Egr-1
expression is significantly increased in patients with cachexia and cancer. This provides new evidence that chronic
activation of systemic inflammatory response might be a common and unifying factor of muscle cachexia.Background
Pancreatic cancer remains one of the most deadly tumor
types, with the highest death-to-incidence ratio of all
cancers. With a 5-year survival rate of less than 5% and
a death-to-incidence ratio of 0.99, pancreatic ductal
adenocarcinoma is currently one of the most aggressive
gastrointestinal carcinomas [1]. The development of
cachexia occurs in most patients with resectable and
with unresectable pancreatic cancer, whose resting
energy expenditure is generally increased. The term* Correspondence: Alexander.Skorokhod@med.uni-heidelberg.de
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tions and descriptions of clinical symptoms of a patient.
It has been shown that a loss of weight exceeding 10%
of the stable pre illness weight is correlated to a worse
prognosis [2].
In the case of muscle wasting associated with cancer,
the balance between protein synthesis and degradation is
shifted markedly toward degradation, and there could be
selective targeting of skeletal muscle gene products by
different cachectic factors such as cytokines and tumor-
derived compounds [3,4]. Weight loss of pancreatic
cancer patients has been also related to the induction of
acute-phase response, resulting in the loss of both fat
and lean tissue. It has been demonstrated that a complex
cascade of inflammatory responses may mediate alter-
ation in metabolic processes, contributing to the devel-
opment of cancer cachexia [5].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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ally present in late stage of the disease, and frequently
develop cachexia syndrome. This emphasizes the im-
portance of early diagnosis, especially with the hope that
intervention may be more effective in the early stages of
disease. This also underscores the need for biomarkers,
which may also contribute to the understanding of cancer
cachexia syndrome [6]. Large-scale analysis of gene
expression has been widely proposed as a powerful
method for malignancy diagnosis, predicting invasion and
metastasis through the identification of biomarkers. To
our knowledge, however, transcriptome-wide analysis of
muscle cachexia in patients has not yet been performed.
Here we present our study that focuses on the identifi-
cation of common differentially expressed genes involved
in muscle wasting progression. We hypothesized that
gene expression patterns in the skeletal muscle of cancer
patients will change under muscle wasting conditions,
and that these changes may determine the initiation and
severity of cachexia syndrome. We suggest that charac-
terizing the skeletal muscle in response to cancer cach-
exia will provide new insights into gene regulation.Methods
Patients
Patients with pancreatic cancer were selected for this
study, as these patients usually experience severe weight
loss (weight loss exceeding 10% of the stable body
weight). All included patients gave written informed con-
sent for tissue and data collection under the local ethics
committee’s permission of the University of Heidelberg.
On admission to hospital, each patient was asked
for his height and current weight. When a patient
gave a history of weight loss, the corresponding time
period was also documented. A patient was classified
as cachectic when weight loss exceeded 10% of the
stable pre-illness weight. It has been shown, that in
patients with a history of weight loss exceeding 10%
of the stable weight, the survival is significantly reduced
[2,7].
Histological diagnosis: Two independent pathologists
from the University of Heidelberg’s Department of Path-
ology confirmed the diagnosis according to the UICC
guidelines [8].Muscle biopsies
Biopsy specimens were obtained from the rectus abdom-
inis muscle of each patient during the initial phase of
the operation. After skin incision and dissection through
the subcutaneous fat, the anterior sheet of the rectus ab-
dominis muscle was opened with scissors and a muscle
biopsy specimen weighing about 50 mg was obtained
and immediately frozen in liquid nitrogen.Real-Imaging cDNA-AFLP transcript profiling
mRNA was extracted from 20 mg rectus abdominis
muscle using MagNA pure LC isolation system accord-
ing to manufacturer’s instructions (Roche). After extrac-
tion, samples were immediately stored at −80°C until
usage. mRNA quality was assessed by reverse transcrip-
tion PCR (RT-PCR) with two housekeeping genes
encoding ribosomal protein L13a (RPL13A) and β-actin.
Negative controls for genomic contamination and
reverse transcription inhibition were included.
The cDNA-AFLP procedure was performed as
described previously with some modifications [9]. cDNA
was synthesized from 100 ng mRNA according to the
manufacturer’s instructions (cDNA Synthesis Kit, Roche).
After restriction enzyme digestion, the cDNA fragments
were ligated to oligomers introducing the priming sites
for TaqI and MseI. The cDNA pools were amplified with
primers TaqI- (5’-CTCGTAGACTGCGTACACGA-3’)
and MseI- (5’-GACGATGAGTCCTGAGTAA-3’).
cDNA-AFLP amplification was performed with 16 pri-
mer pairs MseI+2 and TaqI+2IRD700 (+2 states for add-
itional two-nucleotide combination at 3’-end of primer)
generating approximately 30,000 amplified fragments
possessing 256 probe sets. IRD-labeled PCR products
were resolved in 40 cm long 6% SequaGel XR gel
(Biozym) using automated DNA sequencer DNAIR 4200
(Li-COR). After 1 h electrophoresis the gel was trans-
ferred onto the green grid paper and vacuum dried on
1.2-mm-thick Whatman paper. The dried gel was
scanned at 700/800 nm (intensity 4.0, resolution 84 μm),
obtaining binary data for differentially expressed tags
(Odyssey Imaging System, Li-COR).
Isolation and analysis of cDNA-AFLP tag fragments
The cDNA fragments of interest were excised from
dried gel, followed by elution in 100 μl TE for 10 min at
95°C. 5 μl were re-amplified with TaqI- and MseI-
primers. Specific fragments were verified by visualizing
5 μl PCR product on a 1.5% agarose gel. The amplified
fragments were directly sequenced with the primers
TaqI-IRD700 and MseI-IRD800 using the SequiTherm
EXCEL II DNA sequencing kit (Epicentre) on the auto-
mated infrared sequencer DNAIR 4200 (Li-COR).
Sequencing data were aligned against BlastX and
BlastN in the publicly available databases and clustered
according to gene ontology using the nodes of the DNA-
Space software package (DNASIS MAX 2.6, Miraibio).
Quantitative RT-PCR
Single-stranded cDNA was synthesized from 100 ng of
mRNA according to the manufacturer’s instructions
(RevertAid, Fermentas). Primers complementary to
target genes were designed using Primer Express Soft-
ware (Life Technologies) to amplify fragments in the
Table 1 Clinical characteristics of patients with pancreatic
cancer with (N=10) and without cachexia (N= 13):
gender and performance status
Parameter No cachexia
(N= 13) N [%]
Cachexia
(N= 10) N [%]
gender male 9 [69.2] 5 [50]
female 4 [30.8] 5 [50]
Karnofsky- Index 70 0 [0] 1 [10]
80 1 [7.7] 2 [20]
90 12 [92.3] 7 [70]
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scripts. A quantitative RT-PCR (qPCR) was performed
with SYBR Green PCR Master Mix using GeneAmp
7300 (Life Technologies). qPCR reactions were per-
formed two times in doublets, and the threshold cycle
numbers were averaged. Levels of expression were nor-
malized against RPL13A and β-actin.
Immunohistochemistry
For immunohistochemistry, 5-μm sections of FFPE tis-
sue were incubated in serum-free protein blocking buffer
for 30 min, followed by overnight incubation at 4°C with
1:200 dilution of Egr-1 antibodies (588, Santa Cruz). A
negative control for non-specific staining was performed
with rabbit IgG. DAKO anti-rabbit polymer-HRPO was
applied for signal visualization according to the manu-
facturer’s instructions (DAKO). Finally, sections were
analyzed with an Olympus BX50 microscope using 40x-
lens and software program “Cell^F 2.5” (Olympus).
Protein extraction and immunoblotting
30 μg total protein lysate from the biopsy homogenate
were electrophoresed on gradient 4-15% SDS-PAA gels
(Bio-RAD). After undergoing electrophoresis, proteins
were transferred semi-dried onto PVDF membrane using
the Semi-Dry Blotter (Bio-RAD). After 1 h blocking, the
membrane was exposed overnight at 4°C to primary
anti-human rabbit Egr-1 antibody (588, Santa Cruz) and
anti-human mouse β-tubulin antibody (3 F3-G2, Santa
Cruz) at 1:200.
After washing the membrane was exposed to appropriate
IRDye-700/800 labeled secondary antibodies: Alexa Fluor
680 goat anti-mouse for β-tubulin (Invitrogen) and IRDye-
800 goat anti-rabbit for Egr-1 (Rockland) at 1:10,000. The
amounts of Egr-1 and β-tubulin were determined and
quantified by densitometric scanning of PVDF membranes
at 700/800 nm (intensity 5.0, resolution 84 μm) using the
ODYSSEY Infrared Imaging System (Li-COR). Individual
band intensities were normalized against β-tubulin.
Statistical analysis
All data are presented as means ± standard deviation.
The significance of differences between groups (cachexia
vs. no cachexia) was tested with Student’s t-test and
Mann–Whitney U test. The statistical package SPSS
for Windows (SPSS) was used for all statistical analyses.




We studied skeletal muscle biopsy samples of 23 patients
diagnosed with histologically proven adenocarcinoma of
the pancreas and treated at the Department of Surgery,University of Heidelberg, between November 2004 and
April 2005. In ten of the patients weight loss exceeded
10% of the stable pre illness weight, while weight loss
was absent or less than 10% of the stable weight in 13
patients. Clinical characteristics of these patients are
summarized in Table 1 and Table 2. Tumor resection
was performed in 17 patients (73.9%). Biopsies of the
rectus abdominis muscle were obtained intraoperatively
from pancreatic cancer patients with cachexia (n = 10) or
without cachexia (n = 13). The resection rate was lower
in patients with cachexia (50% vs. 92.3% P= 0.025). The
median age was 65 years for cachectic patients and
66 years for non-cachectic patients, with lower and
upper quartiles of 57 and 74 years for cachectic patients
and 51 and 69 years for non-cachectic patients, with no
significant difference between the examined groups.
There was no significant difference in the performance
status between patients with and without cachexia: every
patient who was referred for operative treatment had a
Karnofsky Index ≥70 (Table 1). In the examined patients
there was no significant difference in CrP-levels in the
serum – as a sign for systemic inflammation – preopera-
tively (P = 0.548). Furthermore, there was also no signifi-
cant difference in protein levels between patients with
and without cachexia (P = 0.19).
Initial staging of these patients was determined
according to the 5th edition of the TNM classification of
the International Union against Cancer. UICC classifica-
tion of operated and examined patients (N = 23) is
shown in Figure 1. Median weight loss of the cachectic
patients was 13.9% of initial body weight within
6 months, compared to 2.1% in the patients without
cachexia (P<0.001).Real-Imaging cDNA-AFLP screening
We performed gene expression profile screening of the
skeletal muscle of pancreatic cancer patients either with
or without cachexia syndrome utilizing Real-Imaging
cDNA-AFLP transcript profiling. Biopsy samples from
10 wasted patients and 13 patients without cachexia
were compared by running the cDNA-AFLP reaction
Table 2 Characteristics of patients with pancreatic cancer






age median (lq/uq) 66 (51/69) 65 (57/74) 0,385
weight loss median (lq/uq) 2,1 (0/5,5) 13,9 (10/19,2) <0.001
CrP median (lq/uq) 7.3 (5.7/11.8) 11.6 (3.1/25.6) 0.548
protein median (lq/uq) 74.9 (70.8/77.9) 71.4 (66.4/75.6) 0.19
resectionrate 12 (92.3) 5 (50) 0.022
stage UICC II 12 (92.3) 4 (40) 0.005
UICC III 1 (6,7) 1 (10)
UICC IV 0 5 (50)
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revealed that amplified tag patterns are almost identical
within one group and differ between the groups (Add-
itional file 1: Figure S1). Therefore, two biopsy samples
from each group were further selected for preparative
Real-Imaging cDNA-AFLP (Figure 2).
Altered expression patterns were readily recognized by
visual inspection and yielded approximately 400 cDNA
fragments (Figure 3A). These cDNA fragments correspond-
ing to differentially accumulating transcripts were excised
from the dried preparative gels (Figure 3B). The accuracy
of band excision was inspected by re-scanning. Sequence
information was obtained by direct sequencing using pri-
mers MseI-IRD700 and TaqI-IRD800 on both strands.Figure 1 UICC Classification of the 23 patients operated for
pancreatic cancer. Distribution of tumor stage of all pancreatic
cancer patients was determined according to the 5th edition of the
TNM classification of the Union International Contre Cancer (UICC).
Median weight loss of the cachectic patients was 13.9% of initial
body weight within 6 months comparing with the patients without
cachexia in which the median weight loss was 2.1% respectively.
The resection rate was lower in patients with cachexia (50% vs.
92.3%) UICC II: without distant metastases; UICC III: infiltration of
celiac trunk and/or mesenteric artery; UICC IV: metastases in liver
and/or peritoneal cavity according to guidelines UICC 2002) in
patients either with (n = 10) or without cachexia (n = 13).Analysis of differentially expressed genes
183 cDNA sequences were identified after a redundancy
check of about 400 isolated tag fragments. They were
clustered into groups according to their annotation
fields. 127 cDNA fragments were referred to the gene
transcripts that predominantly activated in cachectic
patients, as well as 56 individual genes whose transcripts
accumulated predominantly in the non-cachectic control
group (Additional file 2: Table S1).
According to group classification, the identified genes
provide molecular counterparts of muscle cachexia re-
sponsible for actin cytoskeleton rearrangement, actin
filament disruption, extracellular matrix dysregulation,
protein degradation, energy expenditure, tissue hypoxia,
immediate early response, and acute-phase response. We
identified a number of differentially expressed genes,
which have already been characterized in relation to can-
cer cachexia or muscle atrophy. However, our results
also indicate that there are other differentially expressed
genes, which play unknown roles in muscle cachexia.
In wasted patients we observed the upregulation in
gene expression of the contractive muscle proteins
(Additional file 2: Table S1), correlating directly with
other findings [10]. Individual differences were found in
expression of the genes belonging to different proteolytic
pathways (Additional file 2: Table S1, “Protein Degrad-
ation”). A number of genes encoding both transcription
and translation factors as well as different ribosomal
proteins were induced in response to muscle cachexia.
In excellent agreement with previous findings, we
observed the upregulation of class O type forkhead tran-
scription factor 1 (FOXO1), which has been implicated
as a key regulator of gene expression during skeletal
muscle atrophy [11]. We have also identified alteration
of the genes that were previously described in associ-
ation with hypoxia (Additional file 2: Table S1, “Hyp-
oxia”). Results of our cDNA-AFLP screening revealed
that the genes encoding acute-phase response (APR)
proteins fibrinogen α (FGA), fibrinogen γ (FGG), α1-
antitrypsin, and α2-macroglobulin are induced in the
skeletal muscle of pancreatic cancer patients with
cachexia.
Validation of cachexia-associated genes with qPCR
The differential gene expression level of 100 transcripts
from cDNA-AFLP screening profile corresponding to
the genes, which are associated with protein degrad-
ation, hypoxia, acute-phase response or with disorder in
muscle tissue development, was validated by quantitative
RT-PCR of the same skeletal biopsy samples (n = 23)
using a Mann–Whitney U test. Candidate genes with a
P-value threshold of 0.05 are presented in Table 3. qPCR
analysis confirmed significant alteration of transcripts
encoding α1-antitrypsin, α2-macroglobulin, fibrinogen α,
Figure 2 cDNA-AFLP Transcript Profiling of pancreatic cancer
patients. cDNA-AFLP tag patterns amplified from mRNA of skeletal
muscle biopsy samples of pancreatic cancer patients either with
cachexia (IRD800-labeled, red bands) or without cachexia
(IRD700-labeled, green bands) were loaded in the same lane
according to their primer combinations and separated in a 8%
denaturing polyacrylamide gel. Data were collected on automated
Infrared Sequencer DNAIR 4200 (Li-COR Biosciences GmbH). Three
different cDNA-AFLP tag profiles (i), (ii) and (iii) of wasted patients (red
bands) were compared with one non-cachectic control (green bands).
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inflammatory cytokine IL-32, and hypoxia-related bHLH
transcription factors Hes-1, DEC1 and DEC2. The gene
expression level of fibrinogen γ (FGG) was not detect-
able by qPCR in our experiment. None of the above
mentioned genes except APR proteins have been previ-
ously correlated with muscle cachexia of cancer patients.
Aberrant overexpression (>60-fold) of Egr-1 gene was
further elucidated.
Egr-1 protein level is highly elevated in wasted
skeletal muscle
To prove our cDNA-AFLP gene profiling strategy, fol-
lowed by qPCR validation, the protein expression levels
of transcription factor Egr-1 were further analyzed
by immunostaining and Western immunoblotting. The
expression sites of Egr-1 protein were identified both
in longitudinal and transverse sections of the skeletal
muscle from patients either with or without cachexia by
immunohistochemical staining with Egr-1 antibodies.
Comparison of tissue sections revealed a significantly
stronger immunohistochemical signal of Egr-1 protein in
the skeletal muscle tissue cells of patients with cachexia,
as indicated by increased fluorescent staining (Figure 4).
Similar results were obtained with fibrinogen α immuno-
histochemical staining (data not shown).
Furthermore, Egr-1 protein (82 kDa) was quantified in
protein extracts from muscle biopsy samples by Western
immunoblotting using densitometric quantitation of
the appropriate bands against β-tubulin by infrared
fluorescence detection directly on the PVDF membrane
(Figure 5). Immunoblotting detection revealed signifi-
cantly higher levels (median rate 10.3, P≤0.005, Student’s
t-test) of Egr-1 expression in all wasted patients with
pancreatic cancer compared with controls (Figure 5C).
Concentrations of Egr-1 protein remained elevated
among all wasted patients. In some non-cachectic con-
trols the expression level of Egr-1 protein was underre-
presented (Figure 5A).
Finally, immunohistochemistry and Western immuno-
blotting analysis confirmed the strong correlation of
Egr-1 within the skeletal muscle of pancreatic cancer
patients in response to cachexia.
Figure 3 Preparative Real-Imaging cDNA-AFLP Screening.
A) cDNA tag patterns were amplified with individual primer
combinations Taq+2 and Mse+2 (Taq+2 was labeled with IRD700).
After electrophoresis, the gel was transferred and dried on green
grid paper and scanned using Odyssey Imaging System (Li-COR
Biosciences GmbH). The lanes are occupied by cachexia-associated
samples (+) and non-cachectic probes (−) allowing direct visual
comparison. Grid coordinates are indicated in millimeters (mm).
B) Differentially expressed tag patterns (marked in red boxes) were
isolated for sequencing analysis.
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Cachexia is present in around 80% of patients with
cancer in advanced stages, inducing marked depletion oflean and fat mass, and in more than 20% of patients
cachexia is responsible for death [12]. Whereas starva-
tion and chronic malnutrition are associated with adap-
tive decreases in metabolic rate, cancer cachexia is
characterized by altered metabolic processes and activa-
tion of catabolic pathways [13].
We hypothesized that alteration in gene expression
within the skeletal muscle in response to advanced pan-
creatic cancer plays a crucial role in the development of
the muscle cachexia syndrome. To test this hypothesis,
we carried out the transcriptome-wide characterization
of skeletal muscle biopsies utilizing the Real-Imaging
cDNA-AFLP approach to identify those genes that are
commonly induced in the skeletal muscle of pancreatic
cancer patients either with or without muscle cachexia.
In contrast to other studies of skeletal muscle cancer
cachexia based on cDNA microarray technique[14,15],
our Real-Imaging cDNA-AFLP approach gives the ability
to identify and annotate expressed genes without prior
sequence knowledge making possible to distinguish
among different transcripts from genes belonging to the
same gene family or splice variants of the same gene. Im-
portantly, our results indicate that molecular signatures of
gene expression appear to be predictive of muscle cach-
exia, before we can measure this in the preoperative col-
lected blood samples as there is no significant difference
in protein levels or CrP-levels to detect. We suggest that
in characterizing the skeletal muscle transcriptome, one
might expect that different signal systems may work in
combination to shift the disease stage of pancreatic cancer
patients towards cachectic conditions.
We observed that transcript levels of contractile pro-
teins in skeletal muscle of patients with cachexia change
in the same direction. We observed more than 6-fold
upregulation of cyclin-dependent kinase inhibitor p21
(Table 3). The mRNA levels of increased p21 mRNA ex-
pression in cachectic patients may reflect increased ac-
tivity of myostatin, a negative regulator of muscle
growth and development which is thought to induce
cachexia [16]. The skeletal muscle mass appears to be
significantly involved in the process of cancer cachexia
in patients with pancreatic cancer, being the potential
target of various tumor products which can activate pro-
tein degradation [17]. All these changes may indicate the
abnormal metabolic processes shifting towards hyperme-
tabolism and negative energy expenditure in patients
with cachexia.
We have also observed the induction of genes encod-
ing basic helix-loop-helix (bHLH) transcription factors
HES1, DEC1, and DEC2, which are primarily associated
with hypoxia (Table 3). As it was reported previously,
hypoxia enhances Notch signaling and activates Notch-
responsive promoters and increases expression of bHLH
transcription factors [18]. HES1 and DEC1 (Table 3) are
Table 3 mRNA expression level of cDNA-AFLP candidate genes – cachexia vs. no cachexia
Gene description Fold change Gene description Fold change
α1-antitrypsin (serpin) 18.61 fibrinogen α 6.65
α2-macroglobulin 4.77 forkhead transcription factor FOXO1A 5.22
ankyrin 0.41 immediate early response 5 (IER-5) 7.72
archvillin 22.04 karyopherin alpha (importin 5) 0.54
breast cancer-associated protein 9.47 mt translational release factor 1 (MTRF 1) 9,68
calsequestrin 1 22.03 myocyte enhancer factor 2 (MEF2) 13.77
cardiomyopathy associated protein 5 15.4 myosin regulatory light chain (MYLC) 5.63
cofilin 2 16.72 myosin heavy chain 7 (MYH7) 4.54
cyclin-dependent kinase inhibitor 1A (p21) 6.54 NK transcript (IL-32) 6.1
bHLH transcription factor DEC1 3.46 synaptopodin (SYNPO) 1.79
bHLH transcription factor DEC2 2.3 titin 4.19
bHLH transcription factor HES1 5.28 vimentin 2.39
early growth response 1 (Egr-1) 61.14 vinculin 2.68
Skorokhod et al. BMC Cancer 2012, 12:265 Page 7 of 9
http://www.biomedcentral.com/1471-2407/12/265immediate downstream targets of Notch signaling inhi-
biting the transcriptional expression and/or function of
lineage-specifying genes involved in myogenesis [19].
Our study demonstrates for the first time that the
genes encoding acute-phase response (APR) proteins fi-
brinogen α, α1-antitrypsin and α2-macroglobulin are
markedly upregulated not only in the liver but also in
the skeletal muscle of wasted patients with pancreatic
cancer (Table 3), which are associated with altered
energy expenditure and increased protein metabolism ofFigure 4 Altered expression of Egr-1 in the skeletal
muscle tissue of wasted pancreatic cancer patients.
Immunohistochemical staining of skeletal muscle tissue shows
significantly enhanced expression of Egr-1 in wasted pancreatic
cancer patients (C, D) compared with non-cachectic patients (A, B).
A, C – longitudinal sections; B, D – transverse sections of skeletal
muscle from pancreatic cancer patients. 40X original magnification.pancreatic cancer patients [20]. It has been shown that
approximately 40 percent of pancreatic cancer patients
show an acute-phase response at the time of diagnosis,
and this amount increases to around 80 percent at the
time of death [21].
While acute-phase response indicates systemic inflam-
mation, the pro-inflammatory cytokines appear to medi-
ate this response. Furthermore, it has been reported that
non-immune tissues such as cardiac and skeletal muscle
appears to express pro-inflammatory cytokines [22]. In
excellent agreement with these facts, we observed 6-fold
upregulation of interleukin IL-32 (Table 3), play an im-
portant role in inflammatory diseases as direct inducer
of TNF-α [23].
Notably, in contrast to the previous study on human
skeletal muscle cancer cachexia [14], we observed a
more than 5-fold upregulation of FOXO1, a key regula-
tor of gene expression during skeletal muscle atrophy
[11] (p<0.05, Table 3). We suppose that it may be
explained by more stringent selection of cachectic
patients in our study with weigh loss criteria from 10 to
19% within 6 months (Table 1).
Importantly, together with an ongoing inflammatory
response we observed the significant induction of early
response genes Egr-1 and IER-5 in wasted pancreatic
cancer patients (p<0.05, Table 3). Conceptually, Egr-1,
the master switch regulating inflammatory parameters,
can be viewed as a main initiator of inflammatory
response, as it is directly involved in “early signal
events”[24,25]. Egr-1 is also recognized as playing a crit-
ical role in the regulation of over 40 target genes, includ-
ing tumor necrosis factor α (TNF-α), interleukin (IL)-1β,
and IL-6, all of which can induce various features of
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Figure 5 Egr-1 protein is markedly induced in skeletal muscle of wasted pancreatic cancer patients. Protein levels of skeletal muscle
EGR-1 and β-tubulin (loading control) were determined by Western immunoblotting showing aberrant upregulation of Egr-1 in skeletal
muscle of patients with cancer cachexia. Western immunoblotting of Egr-1 (green band, 82 kDa) and β-tubulin (red band, 55 kDa) compares
(A) two non-cachectic with two cachexia-associated biopsy protein extracts and (B) one non-cachectic probe with three cachexia-associated
skeletal muscle biopsy samples. Similar results were obtained in three independent experiments. M – coomassie-blue prestained protein
marker. Full-length blots/gels are presented in Additional file 3: Figure S2. (C) Densitometric analysis of Egr-1 protein expression. Median
rate = 10.23, P-value≤ 0.005 according to Student’s t-test.
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sponse gene expression, the Egr-1 may serve as a bio-
marker of muscle cachexia syndrome.Conclusions
This report provides the first evidence that Egr-1 is aber-
rantly upregulated under conditions of muscle wasting,
underlining the general importance of pro-inflammatory
response in cancer cachexia (Figures 4 and 5). Together
with altered IER-5 and ongoing acute-phase response,
it adds to the body of evidence that systemic inflam-
matory response contributes mainly to cancer cachexia
progression mediating altered metabolic processes, con-
sidering this condition as a chronic systemic inflamma-
tory disease.
In summary, taken together with previous works in
the field, the current study supports a model of muscle
wasting in which the major influence of cancer cachexia
is based on the chronic inflammatory effects resulting in
onset of acute-phase response. Furthermore, this report
provides new insights into the inflammatory response
involved in initiation and progression of cachexia by the
activation of pro-inflammatory transcription factor Egr-1
and acute-phase response. How they are transduced to
initiate the muscle cachexia remains to be investigated.Additional files
Additional file 1: Figure S1. cDNA-AFLP: Comparison of 10 cachectic
and 13 non-cachectic patients using one-primer-pair combination.
Additional file 2: Table S1. Candidate biomarkers for cachexia
progression. Legend: diff. - differential gene expression: ”+” cachexia-
specific upregulation,“-“cachexia-specific downregulation.
Additional file 3: Figure S2. Full-length Western blotting of Egr-1.Abbreviations
cDNA-AFLP: cDNA amplified fragment-length polymorphism; Egr-1: early
growth response; 1IER-5: immediate early response 5; APR: Acute-phase
response.
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